| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2160191 | Radiotherapy and Oncology | 2008 | 6 Pages |
Abstract
Outcome after radiochemotherapy (RCHT) with temozolomide (TMZ) versus radiotherapy (RT) for WHO grade III astrocytic tumors was evaluated.No significant difference in overall survival or progression-free survival between both groups was calculated. RCHT seems not to result in an improved outcome. Further randomized studies are needed to support these results.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stephanie E. Combs, Monika Nagy, Lutz Edler, Renate Rausch, Marc Bischof, Thomas Welzel, Jürgen Debus, Daniela Schulz-Ertner,